We further explored whether a selective NLRP3 inhibitor MCC950 could alleviate NEC-related intestinal and neuroinflammation, especially long-term cognitive impairments, therefore providing a new potential therapeutic strategy for NEC. The gene discussed is NLRP3; the disease is Cognitive impairment.